

Aristada Initio®
(aripiprazole extended-release injection)
Effective 04/01/19

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Aristada Initio® is a prodrug of aripiprazole indicated for the initiation of Aristada®, in combination with oral aripiprazole, when used for the treatment of schizophrenia in adults.

Coverage Guidelines

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. Member is ≥18 years of age.
2. Member is being initiated to treatment with Aristada for treatment of adult schizophrenia.

Note: Additional criteria may apply for members < the age of 18. Please refer to the MassHealth Pediatric Behavioral Health Medication Initiative guideline for criteria.

Limitations

1. Initial approvals will be for 1 injection x 1 month.
2. ARISTADA INITIO is only to be used as a single dose to initiate ARISTADA treatment or as a single dose to re-initiate ARISTADA treatment following a missed dose of ARISTADA.

References

1. Aristada Initio [package insert]. Waltham, MA: Alkermes Inc; 2018

Review History

02/20/19 – Reviewed in P&T Meeting